Burlingame, Feb. 20, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global genetic chronic obstructive pulmonary disease (COPD) market is estimated to be valued at US$ 560.3 million in 2022 and is expected to exhibit a CAGR of 3.2% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market:
Increasing approval of generic drugs by regulatory bodies to treat chronic obstructive pulmonary disease is expected to drive the market growth over the forecast period. For instance, in April 2019, Circassia Pharmaceuticals, Inc., a pharmaceutical company, announced that it had received an approval from the U.S. Food and Drug Administration medication for Duaklir Pressair, treatment for people with chronic obstructive pulmonary disease (COPD). Aclidinium bromide, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta agonist (LABA), are combined in Duaklir Pressair as a fixed-dose medication. Using a pre-loaded, breath-activated Pressair multi-dose inhaler, it is given twice day.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5512
Key Market Takeaways:
Global genetic chronic obstructive pulmonary disease (COPD) market is expected to exhibit a CAGR of 3.2 % during the forecast period due to increasing prevalence chronic obstructive pulmonary disease For instance, according to American Lung Association, in 2018, 9.0 million adults, or 3.6% of those aged 18 or older, had chronic bronchitis. In 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD).
Among distribution channel, the hospital pharmacies segment is expected to dominate the segment growth over the forecast period, owing to the increased prevalence of chronic obstructive pulmonary disease and increasing surgeries for chronic obstructive pulmonary disease. For instance, according to the data published by the Center For Disease Control And Prevention, the global prevalence of chronic obstructive pulmonary disease was 10·3% in 2019, accounting for 391·9 million cases among people aged 30–79 years. Age-adjusted death rates for COPD were significantly lower in 2019 compared with 1999 among U.S. men (57.0 per 100,000 in 1999 and 40.5 per 100,000 in 2019) and among U.S. women (35.3 per 100,000 in 1999 and 34.3 per 100,000 in 2019).
Competitive Landscape:
Key players operating in the global genetic chronic obstructive pulmonary disease (COPD) market include GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5512
Market Segmentation:
- Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
- Bronchodilators
- Phosphodiesterase Type 4 Inhibitors
- Steroids
- Antibiotics
- Others
- Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
- Oral
- Nasal
- Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Peptide Therapeutics Market, By Product Type (Branded Peptide and Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030
Poultry Vaccine Market, Poultry Vaccine Market, By Disease (Bronchitis, Avian Influenza, Newcastle disease, Marek's Disease, and Other Diseases), By Technology (Live Attenuated Vaccines (LAV), Recombinant Vaccines, Inactivated Vaccines, and Other Technologies), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
